e-learning
resources
Berlin 2001
Monday 24.09.2001
Problems in treatment of TB
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Therapeutical problems related to drug-resistance in terms of DOTS
A. A. Torossian, A. Garova, G. Belev, V. Hodgev, S. Kartev, P. Mandulova (Plovdiv, Bulgaria)
Source:
Annual Congress 2001 - Problems in treatment of TB
Session:
Problems in treatment of TB
Session type:
Thematic Poster Session
Number:
2077
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. A. Torossian, A. Garova, G. Belev, V. Hodgev, S. Kartev, P. Mandulova (Plovdiv, Bulgaria). Therapeutical problems related to drug-resistance in terms of DOTS. Eur Respir J 2001; 16: Suppl. 31, 2077
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Impact of drug resistance among new cases on outcome of DOTS category I
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Impact of social support programme on MDR-TB patients' treatment outcomes
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Particular aspects of TB endemia in Bucharest after adoption DOTS strategy
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Year: 2012
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
MDR-TB guidelines: what is new on clinical management
Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management
Year: 2020
Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus
Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health
Year: 2013
Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications
Source: Annual Congress 2009 - Tuberculosis control
Year: 2009
Spectrum of adverse drug reactions during MDR TB treatment
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Poor treatment outcomes of XDR-TB patients in resource-limited settings
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020
Year: 2021
Two major problems in TB patients today: MDR and the abandoned therapy
Source: Annual Congress 2011 - Challenges in tuberculosis control
Year: 2011
Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?
Source: Eur Respir J 2013; 42: 1449-1453
Year: 2013
Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016
How does primary health care providers‘ pre-knowledge on tuberculosis affect the implementation of DOTS strategy in Serbia?
Source: Eur Respir J 2006; 28: Suppl. 50, 19s
Year: 2006
Could side effects of MDR-TB treatment change the outcome of the disease?
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
Impact of applying the DOTS strategy on the TB endemic evolution in Bucharest
Source: Eur Respir J 2007; 30: Suppl. 51, 422s
Year: 2007
Outcomes of DOTS and DOTS Plus regimens implementing among patients with pulmonary tuberculosis relapses
Source: Eur Respir J 2002; 20: Suppl. 38, 369s
Year: 2002
MDR-TB and XDR-TB: drug resistance and treatment outcomes
Source: Eur Respir J 2009; 34: 778
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept